A Phase 0 study of **Infigratinib** in recurrent high-grade glioma participants scheduled for resection to evaluate CNS Penetration with PK triggered expansion cohort

**Inclusion Criteria**
- Progression following Stupp regimen
- Surgical recommendation
- Sufficient archival tissue for eligibility testing that demonstrates:
  - FGFR1 K656E or FGFR3 K650E mutation or FGFR3-TACC3 translocation from NGS sequencing or IHC and RT-PCR
  - ECOG ≤ 2

**Exclusion Criteria**
- Corneal or retinal disorder/keratopathy
- History of liver transplant
- Endocrine alterations of calcium/phosphate homeostasis
- Have used amiodarone within 90 days prior to first dose
- Current use of coumarin-derived anticoagulation
- Current use of carbamazepine, phenytoin, phenobarbital, and primidone
- Prior therapy with any MEK or FGFR inhibitor
- Significant cardiac disease
- QTcF > 470 msec

**Dosing regimen – Phase 0**
Infigratinib = 125mg PO QD x7 days

**Dosing regimen – Phase 2 (28-day cycles)**
Infigratinib = 125mg PO QD x21 days